The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

2005 • 7,244 citations

Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity

2004 • 1,075 citations

CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment

2005 • 910 citations

The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.

2007 • 894 citations

Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor Paroxetine

2003 • 829 citations

Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

2009 • 779 citations

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

2005 • 779 citations

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

2002 • 747 citations

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

2000 • 726 citations

Comprehensive Evaluation of Tamoxifen Sequential Biotransformation by the Human Cytochrome P450 System in Vitro: Prominent Roles for CYP3A and CYP2D6

2004 • 638 citations

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation

2008 • 566 citations

Cytochrome P450 pharmacogenetics and cancer

2006 • 557 citations

The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen

2006 • 554 citations

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

2009 • 518 citations

A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY

1977 • 502 citations

Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes

2007 • 468 citations

Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment

2006 • 464 citations

Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen

2004 • 444 citations

Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes

2002 • 423 citations

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

2010 • 422 citations

CYP2D6 and tamoxifen: DNA matters in breast cancer

2009 • 319 citations

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients

2005 • 302 citations

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

2005 • 290 citations

Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

2007 • 284 citations

Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast Cancer

2007 • 272 citations

Phase III Evaluation of Fluoxetine for Treatment of Hot Flashes

2002 • 250 citations

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients

2005 • 243 citations

Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women

2009 • 230 citations

Significant Effect of Polymorphisms in CYP2D6 and ABCC2 on Clinical Outcomes of Adjuvant Tamoxifen Therapy for Breast Cancer Patients

2010 • 222 citations

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells

2009 • 211 citations

Impact of CYP2D6*10 on recurrence‐free survival in breast cancer patients receiving adjuvant tamoxifen therapy

2008 • 181 citations

Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment

2008 • 176 citations

Steroid sulfation by expressed human cytosolic sulfotransferases

1994 • 175 citations

Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis

2009 • 172 citations

Effect of Concomitant CYP2D6 Inhibitor Use and Tamoxifen Adherence on Breast Cancer Recurrence in Early-Stage Breast Cancer

2010 • 166 citations

Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Sertraline (Zoloft) for the Treatment of Hot Flashes in Women with Early Stage Breast Cancer Taking Tamoxifen

2006 • 156 citations

Pharmacogenomics of Tamoxifen Therapy

2009 • 150 citations

Pharmacogenetics of human cytosolic sulfotransferases

2006 • 150 citations

Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer Cells

2006 • 134 citations

The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liver

2002 • 129 citations

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

2009 • 125 citations

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

2009 • 119 citations

Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients

2008 • 113 citations

Genotype-guided tamoxifen therapy: time to pause for reflection?

2009 • 113 citations

Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases

2002 • 105 citations

Glucuronidation of Active Tamoxifen Metabolites by the Human UDP Glucuronosyltransferases

2007 • 95 citations

Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

2008 • 89 citations

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

2009 • 85 citations

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

2009 • 83 citations

Pharmacogenetics in Breast Cancer Therapy

2008 • 79 citations

Clinical Implications of CYP2D6 Genotyping in Tamoxifen Treatment for Breast Cancer

2008 • 75 citations

Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors

2009 • 66 citations

Pharmacogenetics of Tamoxifen: Who Should UndergoCYP2D6Genetic Testing?

2009 • 57 citations

Up-Front Use of Aromatase Inhibitors As Adjuvant Therapy for Breast Cancer: The Emperor Has No Clothes

2009 • 53 citations

No Increase in Breast Cancer Recurrence with Concurrent Use of Tamoxifen and Some CYP2D6-Inhibiting Medications

2009 • 51 citations

Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4

2006 • 48 citations

Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen

2007 • 41 citations

Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy

2008 • 39 citations

Tamoxifen: the drug that came in from the cold

2009 • 35 citations

Adjuvant Tamoxifen Treatment Outcome According to Cytochrome P450 2D6 (CYP2D6) Phenotype in Early Stage Breast Cancer: Findings from the International Tamoxifen Pharmacogenomics Consortium.

2009 • 30 citations

Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiological study

2009 • 27 citations

CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen

2007 • 21 citations

Pharmacogenetic (CYP2D6) and gene expression profiles (HOXB13/IL17BR and molecular grade index) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial.

2009 • 15 citations

Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues

2009 • 14 citations

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy

2010 • 11 citations

Tamoxifen pharmacogenetics of CYP2D6, CYP2C19, and SULT1A1: long term follow-up of the North Central Cancer Treatment Group 89-30-52 adjuvant trial.

2009 • 7 citations